文献速递细菌感染、耐药与抗菌药物

新型糖肽类抗生素治疗复杂性皮肤软组织感染:系统综述、网状Meta分析与成本分析

Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis.
PubMed 文献 · Clin Microbiol Infect · 2017-09-04

该研究通过系统综述、网状Meta分析和成本分析比较新型糖肽类(特拉万星、达巴万星、奥利万星)与标准治疗及彼此间治疗复杂性皮肤软组织感染的疗效与成本。七项RCT显示三者临床应答与标准治疗相似,特拉万星不良事件较多,达巴万星和奥利万星可节省第三方支付费用。

要点

  • 达巴万星和奥利万星治疗cSSTI的疗效与标准治疗相当,且不良事件较少。
  • 特拉万星总体不良事件发生率高于标准治疗(OR 1.33)。
  • 达巴万星和奥利万星较标准治疗可降低cSSTI治疗成本。

核心结论

  • 在高质量RCT中,达巴万星和奥利万星的疗效与安全性不劣于标准治疗,且当标准治疗覆盖MRSA时可节省费用。

研究设计与样本

  • 系统综述、网状Meta分析与成本分析,纳入7项随机对照试验,数据来源Medline、Embase和Cochrane Central。

主要发现

  • 特拉万星、达巴万星、奥利万星临床应答与标准治疗相似,OR分别为1.09(95%CI 0.90-1.33)、0.78(95%CI 0.52-1.18)、1.06(95%CI 0.85-1.33)。
  • 头对头比较显示奥利万星与达巴万星(OR 1.36,95%CI 0.85-2.18)、奥利万星与特拉万星(OR 0.98,95%CI 0.72-1.31)、达巴万星与特拉万星(OR 0.72,95%CI 0.45-1.13)临床应答无差异。
  • 特拉万星总体不良事件发生率高于标准治疗(OR 1.33,95%CI 1.10-1.61);达巴万星(OR 0.58,95%CI 0.45-0.76)和奥利万星(OR 0.71,95%CI 0.55-0.92)不良事件少于特拉万星。

关键数值与推荐

  • 临床应答OR:特拉万星 vs 标准治疗1.09(95%CI 0.90-1.33),达巴万星 vs 标准治疗0.78(95%CI 0.52-1.18),奥利万星 vs 标准治疗1.06(95%CI 0.85-1.33)。
  • 不良事件OR:特拉万星 vs 标准治疗1.33(95%CI 1.10-1.61),达巴万星 vs 特拉万星0.58(95%CI 0.45-0.76),奥利万星 vs 特拉万星0.71(95%CI 0.55-0.92)。
  • 成本分析:达巴万星每例cSSTI可节省1442至4803美元,奥利万星每例可节省3571至6932美元。

临床怎么用

  • 对于cSSTI,达巴万星和奥利万星可作为标准治疗的替代选择,兼具疗效、安全性和成本优势。
  • 特拉万星因不良事件较多,需权衡利弊后使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Skin and soft tissue infections (SSTIs) carry significant economic burden, as well as morbidity and mortality, especially when caused by methicillin-resistant Staphylococcus aureus (MRSA). Several new MRSA-active antibiotics have been developed, including semisynthetic glycopeptides (telavancin, dalbavancin and oritavancin). Of these, dalbavancin and oritavancin offer extended dosing intervals. METHODS: We performed a systematic review, network meta-analysis and cost analysis to compare the newer glycopeptides to standard care and to each other for the treatment of complicated SSTIs (cSSTI). A search for randomized controlled trials (RCTs) was conducted in Medline, Embase and the Cochrane Central Register of Controlled Trials. We also developed a model to evaluate the costs associated with dalbavancin and oritavancin from the third-party payer perspective. RESULTS: Seven RCTs met the inclusion criteria. Network meta-analyses suggested that the clinical response to telavancin, dalbavancin and oritavancin was similar to standard care (odds ratio (OR) 1.09, 95% confidence interval (CI) 0.90-1.33; OR 0.78, 95% CI 0.52-1.18; and OR 1.06, 95% CI 0.85-1.33, respectively). Head-to-head comparisons showed no difference in clinical response between oritavancin and dalbavancin (OR 1.36; 95% CI 0.85-2.18), oritavancin and telavancin (OR 0.98; 95% CI 0.72-1.31) or dalbavancin and telavancin (OR 0.72; 95% CI 0.45-1.13). Telavancin had a higher incidence of overall adverse events compared to standard care (OR 1.33; 95% CI 1.10-1.61). Compared to telavancin, there were fewer overall adverse events with dalbavancin (OR 0.58; 95% CI 0.45-0.76) and oritavancin (OR 0.71; 95% CI 0.55-0.92). Studies were of high quality overall. Our cost analyses demonstrated that dalbavancin and oritavancin were less costly compared to standard care under baseline assumptions and many scenarios evaluated. The use of dalbavancin could save third-party payers $1442 to $4803 per cSSTI, while the use of oritavancin could save $3571 to $6932 per cSSTI. CONCLUSIONS: Dalbavancin and oritavancin demonstrate efficacy and safety comparable to standard care in well-designed RCTs and result in cost savings when standard care is treatment that covers MRSA.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Agarwal R, Bartsch SM, Kelly BJ, et al. Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis. Clin Microbiol Infect. 2017. PMID: 28882727. doi:10.1016/j.cmi.2017.08.028

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。